Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

被引：0
|
作者：
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
机构：
[1] Sorbonne Univ, Hop St Antoine, Paris, France
[2] INSERM UMRs938, Paris, France
[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[4] Hop St Louis, Paris, France
[5] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[6] Epworth Healthcare, Melbourne, Vic, Australia
[7] Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY USA
[8] Univ Navarra Clin, Madrid, Spain
[9] Hosp Univ 12 OCTUBRE, Madrid, Spain
[10] Miami Canc Inst, Miami, FL USA
[11] Indiana Blood & Marrow Transplant, Indianapolis, IN USA
[12] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[13] Norton Canc Inst, Louisville, KY USA
[14] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA
[15] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[16] Nagoya City Univ, Dept Hematol & Oncol, Grad Sch Med Sci, Nagoya, Aichi, Japan
[17] Pfizer Inc, Cambridge, MA USA
[18] Pfizer Inc, New York, NY USA
[19] Pfizer SLU, Madrid, Spain
[20] Mem Sloan Kettering Canc Ctr, Div Hematol & Oncol, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8039
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    Nahi, Hareth
    Krishnan, Amrita Y.
    van de Donk, Niels W. C. J.
    San Miguel, Jesus
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Adams, Homer
    Girgis, Suzette
    Lin, Shun Xin Wang
    Stephenson, Tara
    Kemmerer, Kristy
    Smit, Jennifer
    Elsayed, Yusri A.
    Infante, Jeffrey R.
    Goldberg, Jenna D.
    Banerjee, Arnob
    Garfall, Alfred L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
    Sun, Mingyuan
    Qi, Junyuan
    Qiu, Lugui
    Jin, Jie
    Li, Xin
    Wei, Yongqiang
    Zhang, Guimin
    Liu, Xue
    Yin, Shaohong
    BLOOD, 2023, 142
  • [34] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
    Sun, Mingyuan
    Qiu, Lugui
    Wei, Yongqiang
    Jin, Jie
    Li, Xin
    Liu, Xue
    Yin, Shaohong
    Qi, Junyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
    Tomasson, Michael H.
    Iida, Shinsuke
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Rodriguez-Otero, Paula
    Prince, H. Miles
    Viqueira, Andrea
    Leip, Eric
    Conte, Umberto
    Sullivan, Sharon T.
    Lesokhin, Alexander M.
    HEMASPHERE, 2024, 8 (07):
  • [36] Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
    Martin, Thomas G.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Nooka, Ajay K.
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Krishnan, Amrita Y.
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez, Joaquin
    Delforge, Michel
    Fastenau, John
    Gries, Katharine S.
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] The effect of elranatamab on patient-reported outcomes in patients with relapsed/refractory multiple myeloma naive and exposed to BCMA-directed therapies: results from the MagnetisMM-3 study
    Mohty, Mohamad
    Bahlis, Nizar
    Nooka, Ajay
    DiBonaventura, Marco
    Ren, Jinma
    Conte, Umberto
    Viqueira, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S300 - S301
  • [38] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Madduri, Deepu
    Rosko, Ashley
    Brayer, Jason
    Zonder, Jeffrey
    Bensinger, William I.
    Li, Jingjin
    Xu, Linzhi
    Adriaens, Lieve
    Chokshi, Dhruti
    Zhang, Weijiang
    Boyapati, Anita
    Sharma, Manish
    Seebach, Frank
    Sirulnik, L. Andres
    Weinreich, David M.
    Yancopoulos, George D.
    Dhodapkar, Madhav V.
    Lentzsch, Suzanne
    Cooper, Dennis
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [39] Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)
    Venkatesh, Priyanka
    Atrash, Shebli
    Paul, Barry
    Alkharabsheh, Omar
    Afrough, Aimaz
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Hashmi, Hamza
    Davis, James A.
    Abdallah, Al-Ola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Usmani, Saad Z.
    Garfall, Alfred
    van de Donk, Niels
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Moreau, Philippe
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
12345